Contact Us
Contact Us

Developing next generation therapeutics targeting immune suppression in cancer.

WHO WE ARE

Our team has a proven track record with immunology expertise in cancer and inflammation.
MEET OUR TEAM

WHAT WE DO

We are developing novel drugs targeting a class of immune cells called myeloid cells to directly treat cancer as well as to enhance the benefits of current Immuno Oncology drugs such as checkpoint inhibitors in currently untreatable cancers.
LEARN MORE

THE SCIENCE

Immuno Oncology (IO) is a new area of cancer research which has been successful in treating previously untreatable cancers. IO targets the immune system rather than the cancer directly which potentially allows a single IO drug to be used to treat multiple cancer types with mostly manageable side effects.

READ MORE

NEWSROOM

Our latest company news and scientific findings.

,

|

10/28/2024

ME THERAPEUTICS HOLDINGS INC. APPOINTS CHIEF BUSINESS OFFICER

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

10/23/2024

ME THERAPEUTICS HOLDINGS INC. PROVIDES RESEARCH AND DEVELOPMENT UPDATE AND CORPORATE UPDATE

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

09/18/2024

ME THERAPEUTICS ANNOUNCES THE START OF TESTING OF FIRST MRNA FORMULATIONS FROM NANOVATION THERAPEUTICS COLLABORATION

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

07/18/2024

ME THERAPEUTICS ANNOUNCES NEW COLLABORATION WITH NANOVATION THERAPEUTICS ON ADVANCED THERAPEUTIC MRNA DELIVERY TO MYELOID CELLS

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

05/29/2024

ME THERAPEUTICS HOLDINGS INC. ANNOUNCES THE ADDITION OF TWO NEW CLINICAL CONSULTANTS TO CONTINUE THE ADVANCEMENT OF OUR LEAD ANTI-G-CSF ANTIBODY CANDIDATE TOWARDS A FIRST-IN-HUMAN CLINICAL TRIAL

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

05/17/2024

ME THERAPEUTICS TO PRESENT AT INVESTOR CLUBHOUSE AT THE CANADIAN OPEN AND ATTEND THE 2024 BIO INTERNATIONAL CONVENTION FOR PARTNERING OPPORTUNITIES

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....
View All

Keep up to date by subscribing to our mailing list

ME Therapeutics Inc.

Links

Social

Get In Touch

ME Therapeutics
177 Robson St.
Vancouver, BC,Canada
V6B 0N3

© 2023 ME Therapeutics All Rights Reserved.

METX (CSE)
Q9T (FSE)